Drugs / REGN14256
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05081388 | Nov 2021 → Jun 2022 | COVID-19 | Regeneron Pharmaceuticals | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | REGN14256 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05081388 ↗ |
| Route | Subcutaneous | “Sub-cutaneous (SC) single dose” NCT05081388 ↗ |